New post-hoc analysis examined daily oral orforglipron in adults over 65 with obesity, with or without diabetes

AI Summary

A recent analysis presented at the European Congress on Obesity focused on the use of daily oral orforglipron for treating obesity in older adults. Results show promises similar to previous studies regarding its safety and efficacy.

A new analysis presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial program population.